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background: Patients taking dual antiplatelet therapy (DAPT) were excluded from ROCKET AF, but those who underwent PCI during the trial were 
allowed to continue study drug. We assessed the use of DAPT and outcomes in those undergoing PCI.
Methods: All patients in the intention-to-treat (ITT) group who underwent PCI were included. Clinical characteristics, PCI frequency, and rates of 
DAPT were reported. Outcomes were adjudicated as part of the trial.
results: Among 14,171 patients in the ITT group, 153 (1.1%) underwent PCI (61 rivaroxaban-treated and 92 warfarin-treated patients). PCI was 
performed with bare-metal stents (44%), drug-eluting stents (34%) and balloon angioplasty alone (16%). Those who underwent PCI were mostly male 
and more likely to have diabetes, prior MI, or PAD. Long-term DAPT (≥30 days) was used in 37% of patients. A small number switched from DAPT to 
monotherapy in <30 days (n=19 [12.3%]). Post-PCI rivaroxaban-treated patients had numerically higher rates of major bleeding and warfarin-treated 
patients had numerically higher rates of stroke and vascular death, though rates were based on very few events (Table). Regression analyses showed 
no interaction between PCI and treatment effect for all outcomes.
conclusions: PCI was infrequent in ROCKET AF. After PCI, long-term DAPT was used in <50% while early switching from DAPT to monotherapy 
occurred in >10% of patients. Further research is needed to determine the best antithrombotic treatment strategy for AF patients undergoing PCI.
Table. Events in patients undergoing PCI in the ROCKET AF trial
Endpoint Rivaroxaban Warfarin
Unadjusted Event Rate/100 pt-yrs (N) No PCI Post-PCI No PCI Post-PCI
N=7020 N=61 N=6999 N=92
Efficacy
Stroke or systemic embolism 2.12 (266) 5.02 (3) 2.42 (302) 4.10 (4)
Stroke 2.01 (252) 1.62 (1) 2.22 (277) 4.08 (4)
Myocardial infarction 0.97 (123) 6.82 (3) 1.03 (130) 5.86 (4)
Vascular death 2.93 (373) 3.12 (2) 3.07 (390) 11.05(11)
Safety
Major bleeding 3.58 (389) 15.01 (6) 3.43 (377) 8.05 (6)
*Note: The “No PCI” group includes patients who did not undergo PCI as well as the time period before PCI in patients who did undergo PCI.
